Opthea’s Wet AMD Program Featured at Ophthalmology Events
Opthea (ASX/NASDAQ: OPT) announced its participation in two major ophthalmology conferences where sozinibercept will be featured. At the 17th Congress of APVRS, Dr. Gregg T. Kokame will present Phase 2b trial data showing that patients with polypoidal choroidal vasculopathy treated with a combination of sozinibercept and ranibizumab achieved significantly better visual and anatomic outcomes compared to ranibizumab alone at 24 weeks. Additionally, CEO Frederic Guerard will present at the Ophthalmology Innovation Summit XIV during the Retina Innovation Showcase.
Opthea (ASX/NASDAQ: OPT) ha annunciato la sua partecipazione a due importanti conferenze di oftalmologia in cui sarà presentato il sozinibercept. Al 17° Congresso dell'APVRS, il Dr. Gregg T. Kokame presenterà i dati della fase 2b di uno studio che dimostrano che i pazienti con vasculopatia coroideale polipoide trattati con una combinazione di sozinibercept e ranibizumab hanno ottenuto risultati visivi e anatomici significativamente migliori rispetto a quelli trattati solo con ranibizumab a 24 settimane. Inoltre, il CEO Frederic Guerard presenterà al Ophthalmology Innovation Summit XIV durante la Retina Innovation Showcase.
Opthea (ASX/NASDAQ: OPT) anunció su participación en dos importantes conferencias de oftalmología donde se presentará el sozinibercept. En el 17° Congreso de la APVRS, el Dr. Gregg T. Kokame presentará datos del ensayo de fase 2b que muestran que los pacientes con vasculopatía coroidea polipoide tratados con una combinación de sozinibercept y ranibizumab lograron resultados visuales y anatómicos significativamente mejores en comparación con aquellos tratados solo con ranibizumab a las 24 semanas. Además, el CEO Frederic Guerard presentará en el Ophthalmology Innovation Summit XIV durante la Retina Innovation Showcase.
Opthea (ASX/NASDAQ: OPT)는 소지노비셉트가 소개될 두 개의 주요 안과 학술 대회에 참여한다고 발표했습니다. 제17회 APVRS 회의에서 Gregg T. Kokame 박사는 폴리포이드 맥락막 혈관병증 환자들이 소지노비셉트와 라니비주맙의 조합 치료를 받을 때 24주 후에 라니비주맙 단독 치료에 비해 시각적 및 해부학적 결과가 유의미하게 개선되었다는 2b상 시험 데이터를 발표할 것입니다. 또한, CEO Frederic Guerard는 Ophthalmology Innovation Summit XIV의 Retina Innovation Showcase에서 발표할 예정입니다.
Opthea (ASX/NASDAQ: OPT) a annoncé sa participation à deux grandes conférences en ophtalmologie où le sozinibercept sera mis en avant. Lors du 17e Congrès de l'APVRS, le Dr. Gregg T. Kokame présentera des données d'essai de phase 2b montrant que les patients atteints de vasculopathie choroïdienne polypoïde traités avec une combinaison de sozinibercept et de ranibizumab ont obtenu des résultats visuels et anatomiques significativement meilleurs par rapport à ceux traités uniquement avec le ranibizumab après 24 semaines. De plus, le PDG Frederic Guerard présentera au Ophthalmology Innovation Summit XIV lors du Retina Innovation Showcase.
Opthea (ASX/NASDAQ: OPT) gab bekannt, dass das Unternehmen an zwei bedeutenden Ophthalmologie-Konferenzen teilnehmen wird, bei denen Sozinibercept vorgestellt wird. Auf dem 17. Kongress der APVRS wird Dr. Gregg T. Kokame Daten aus der Phase-2b-Studie präsentieren, die zeigen, dass Patienten mit polypoider choroidaler Vaskulopathie, die mit einer Kombination aus Sozinibercept und Ranibizumab behandelt wurden, im Vergleich zu nur mit Ranibizumab behandelten Patienten nach 24 Wochen signifikant bessere visuelle und anatomische Ergebnisse erzielten. Darüber hinaus wird CEO Frederic Guerard auf dem Ophthalmology Innovation Summit XIV während der Retina Innovation Showcase präsentieren.
- Phase 2b trial data demonstrates significantly better outcomes for combination therapy versus standard treatment
- Positive clinical results in polypoidal choroidal vasculopathy (PCV) subgroup
- None.
17 Congress of the Asia-Pacific Vitreo-Retina Society, November 22 - 24, 2024
Ophthalmology Innovation Summit XIV, November 23, 2024
MELBOURNE, Australia, and PRINCETON, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Opthea and sozinibercept will be highlighted during two upcoming Ophthalmology conferences.
Conference details are as follows:
The 17th Congress of the Asia-Pacific Vitreo-Retina Society (APVRS)
| Session: | Rapid Fire 4 – Retina (Medical & Surgical) | |
| Timing: | Friday, November 22, 2024, 3:15 – 3:20 PM Singapore time (GMT+8) | |
| Presentation: | Intravitreal Sozinibercept (anti-VEGF-C/-D ‘trap’) Combined with Ranibizumab for the Treatment of Polypoidal Choroidal Vasculopathy: A Predefined Phase 2b Subgroup Analysis | |
| Presenter: | Gregg T. Kokame, MD, MMM, FASRS | |
| Abstract: | https://2024.apvrs.org/abstract/?code=200963 | |
Gregg T. Kokame, MD, MMM, FASRS, will present data from a predefined subgroup of the sozinibercept Phase 2b wet AMD trial related to patients with polypoidal choroidal vasculopathy (PCV), measured at 24 weeks. Data from this subgroup show that patients treated with a combination of sozinibercept and ranibizumab experienced significantly better visual and anatomic outcomes compared to ranibizumab alone.
APVRS, themed Transforming Retinal Disease Management with Technology, gathers a distinguished international faculty of top specialists in vitreo-retina to share their expertise and experience. The scientific program will focus on exciting areas such as novel surgical innovations
and therapies, and latest advances in imaging and research.
Ophthalmology Innovation Summit XIV (OIS)
| Session: | Retina Innovation Showcase | |
| Timing: | Saturday, November 23, 2024, 11:15 AM – 12:50 PM PT | |
| Presenter: | Frederic Guerard, PharmD, CEO, Opthea | |
| Agenda: | https://ois.net/ois-xiv-agenda/ | |
The Ophthalmology Innovation Summit connects clinical, corporate, and capital leaders to drive the ophthalmic market forward. It showcases groundbreaking advancements and clinical insights in both anterior and posterior ophthalmology segments and offers the opportunity to learn, network and collaborate.
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Authorized for release to ASX by Frederic Guerard, PharmD, CEO
Investor Inquiries
PJ Kelleher
LifeSci Advisors, LLC
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579
Media Inquiries
Silvana Guerci-Lena
NorthStream Global Partners
Email: silvana@nsgpllc.com
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com
Source: Opthea Limited
FAQ
What were the results of Opthea's (OPT) Phase 2b trial for sozinibercept in PCV patients?
When will Opthea (OPT) present its sozinibercept data at APVRS 2024?
Where will Opthea (OPT) showcase its wet AMD program in November 2024?
